KAKEN PHARMACEUTICAL
Japan
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
Phase 1
Recruiting
- Conditions
- Healty Volunteers
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 36
- Registration Number
- NCT06821698
- Locations
- 🇺🇸
Parexel International Early Phase Clinical Unit, Glendale, California, United States
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults
Phase 1
Active, not recruiting
- Conditions
- Healthy Volunteers - Male and Female
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 40
- Registration Number
- NCT06649942
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT06619054
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 38
- Registration Number
- NCT06227832
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 25
- Registration Number
- NCT01015404
- Locations
- 🇯🇵
Kaken Investigational Site 2, Matsudo, Japan
🇯🇵Kaken Investigational Site 1, Sapporo, Japan
🇯🇵Kaken Investigational Site 4, Shinjuku-ku, Japan
A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: KP-413 Ointment
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 58
- Registration Number
- NCT00932074
- Locations
- 🇺🇸
Oregon Medical Research Center, PC, Portland, Oregon, United States
🇺🇸Michigan Center for Research Corp, Clinton Twp., Michigan, United States
🇺🇸J & S Studies, Inc., College Station, Texas, United States
Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)
Phase 3
Completed
- Conditions
- PeriodontitisAlveolar Bone LossPeriodontal Attachment Loss
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 328
- Registration Number
- NCT00734708
- Locations
- 🇯🇵
Kaken Investigational Site, Tokushima, Japan
Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2
Phase 2
Completed
- Conditions
- Periodontitis
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2007-08-10
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 91
- Registration Number
- NCT00514657
A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-02-05
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 267
- Registration Number
- NCT00199290
- Locations
- 🇯🇵
Kaken Investigational Site, Tokushima, Japan
© Copyright 2025. All Rights Reserved by MedPath